Terns investors believe Merck’s $53 acquisition offer undervalues the company—arbitrage involves the possibility of competing bids or the deal falling through

Merck launched a $53/share cash tender for Terns Pharmaceuticals (~$6.7B equity value, ~ $5.7B net after cash), a 6% premium to the pre-announcement close; Terns traded at $52.78 on Apr 6, implying market skepticism. Key risks: the tender requires >50% shareholder participation, potential antitrust/regulatory scrutiny, and the possibility of competing bids (offer expiry May 4, 2026; closing expected Q2 2026). Arbitrageers face a binary outcome: deal closes at $53 or shares fall if the offer fails or a rival bidder emerges.

Analysis

The structure of this tender—majority vote plus a fixed cash price—creates a classic coordination problem among large holders that is the real driver of the spread. If a handful of index/ETF and long-only holders are reluctant to tender because they expect a higher bid, the deal can fail even if strategic buyers privately value the asset materially more; monitor ownership concentration and historical tender behavior of top 10 holders for an accurate close-probability signal.

A competing-bid scenario is asymmetric: a rival acquirer needs only to justify a higher multiple to dislodge the process, whereas Merck can walk away with limited downside to corporate strategy if the asset remains independent. That asymmetry makes takeover activism or a strategic interloper the highest-impact, shortest-latency catalyst — expect price moves inside weeks if any credible stalking-horse emerges rather than drawn-out regulatory fights.

Event-driven managers should treat this as a short-duration binary with idiosyncratic tail risk from clinical/regulatory updates; clinical news or an updated analyst model can move the fallback value by multiples. Operationally, liquidity and borrow cost dynamics (for both stock and options) will dominate execution P&L, so layer entries and size relative to expected VaR, not conviction alone.

Contrarian read: the market is underestimating the probability that the board and a subset of index-friendly holders will tender to avoid proxy complexity and litigation; that increases the expected close probability relative to headline skepticism. If correct, small, well-hedged long-arb stakes win with attractive Sharpe but require tight monitoring for a competing-bid shock.

Key Decisions for Investors

• Event-arb long TERN (size 2-4% NAV) through May expiry: stagger entries, target capture = current spread (tight, single-digit), stop-loss if price trades >8-10% below today’s level or if 13D/13G shows major non-tender intent. Timeframe: near-term (weeks). Risk/Reward: asymmetric — small guaranteed-ish return if close, ~30-60% downside if deal fails.
• Hedge-biotech beta: pair long TERN with a short biotech basket (e.g., IBB or 5-10% notional) to neutralize sector moves while preserving event upside. Timeframe: through deal close. Risk/Reward: reduces market noise; keeps directional exposure to deal outcome.
• Tail-opportunity: buy 3–6 month call spreads on likely strategic bidders (ABBV/BMY) sized 0.5–1% NAV to capture a takeover re-rate if a competitive bid appears. Risk/Reward: limited premium loss vs. asymmetric upside (single-digit to double-digit % move in bidder equity).
• If conviction leans to failure, short TERN or buy puts expiring 1–3 months out (check borrow cost first); keep position small and time-decay aware. Timeframe: immediate to 1 quarter. Risk/Reward: direct downside exposure if coordination fails, but borrow squeeze/short-covering risk if a higher bidder emerges.